Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03309579 · ClinicalTrials.gov registry record · NA
SAHaRA: A Randomized Controlled Trial
A NA study, sponsored by Ottawa Hospital Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 742
- Enrollment target
NCT03309579: Completed NA study, sponsored by Ottawa Hospital Research Institute.
NCT03309579 is a NA study that has completed, run by Ottawa Hospital Research Institute. The registered enrollment target is 742 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03309579, a NA study, has completed, sponsored by Ottawa Hospital Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 742 participants
- Enrollment target
Study Summary
The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.
Primary Outcome
The Modified Rankin Scale (mRS) is a functional outcome measure in stroke. The interview consists of five sections: Constant Care, Assistance to Attend to Bodily Needs/For Walking, Assistance to Look After Own Affairs, Usual Duties and Activities and Symptoms as a Result of Stroke. The scale is scored from 0 reporting no symptoms at all, to 5 reporting severe disability. Death is indicated by a score of 6.
Interventions
- OTHER Liberal RBC Transfusion Strategy
- OTHER Restrictive RBC Transfusion Strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2024-08-22 |
| Phase | NA |
What the finished NCT03309579 record still lists
NCT03309579 is an interventional study that assigns participants to a tested intervention. The registered 742 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Liberal RBC Transfusion Strategy is the first listed.
NCT03309579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03309579 about?
NCT03309579 is a clinical study titled "SAHaRA: A Randomized Controlled Trial". The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strate...
What is the current status of trial NCT03309579?
This trial is currently completed. It is a NA study. The enrollment target is 742 participants. The study started on 2018-02-12. Estimated completion is 2024-08-22.
What interventions are being tested in trial NCT03309579?
The interventions under investigation include: Liberal RBC Transfusion Strategy (OTHER), Restrictive RBC Transfusion Strategy (OTHER).
Who is sponsoring clinical trial NCT03309579?
This trial is sponsored by Ottawa Hospital Research Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03309579's enrollment target sits among peer trials
742 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05786417 · 741 participants · Phase 4
LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
- NCT06556563 · 741 participants · Phase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI